Revolutionary approach for treating glioblastoma works with human cells
In a rapid-fire series of breakthroughs in just under a year, researchers at the University of North Carolina at Chapel Hill have made another stunning advance in the development of an effective treatment for glioblastoma, a common and aggressive brain cancer. The work, published in the Feb. 1 issue of Science Translational Medicine, describes how human stem cells, made from human skin cells, can hunt down and kill human brain cancer, a critical and monumental step toward clinical trials – and real treatment.
Last year, the UNC-Chapel Hill team, led by Shawn Hingtgen, an assistant professor in the Eshelman School of Pharmacy and member of the Lineberger Comprehensive Cancer Center, used the technology to convert mouse skin cells to stem cells that could home in on and kill human brain cancer, increasing time of survival 160 to 220 percent, depending on the tumor type. Now, they not only show that the technique works with human cells but also works quickly enough to help patients, whose median survival is less than 18 months and chance of surviving beyond two years is 30 percent.
“Speed is essential,” Hingtgen said. “It used to take weeks to convert human skin cells to stem cells. But brain cancer patients don’t have weeks and months to wait for us to generate these therapies. The new process we developed to create these stem cells is fast enough and simple enough to be used to treat a patient.”
Surgery, radiation and chemotherapy are the standard of care for glioblastoma, and that hasn’t changed in three decades. In months, the tumor comes back in almost every single patient, invariably sending tiny tendrils out into the surrounding brain tissue. Drugs can’t reach them, and surgeons can’t see them, so it’s almost impossible to remove all of the cancer, explained Ryan Miller, a coauthor of the study and neuropathologist at UNC Hospitals and associate professor at the UNC School of Medicine.
“We desperately need something better,” said Hingtgen.
The key to Hingtgen’s treatment is “skin flipping,” a technology for creating neural stem cells from skin cells that won a Nobel Prize in 2012. The first step is to harvest fibroblasts — skin cells responsible for producing collagen and connective tissue — from the patient and reprogram those cells to become what are called induced neural stem cells, which have an innate ability to home in on cancer cells in the brain.
But by themselves, stem cells can only find a tumor and bump up against it – not kill it – so the team had to engineer stem cells that could carry therapeutic agents that the cells can launch at the tumor to kill it.
Hingtgen’s stem cells can carry a protein that activates an inert substance called a prodrug that is given to the patient. The cells can then generate a small halo of drug that is located just around the stem cell, rather than it being circulated throughout the patient’s body, reducing unwanted side effects.
“We’re one to two years away from clinical trials, but for the first time, we showed that our strategy for treating glioblastoma works with human stem cells and human cancers,” said Hingtgen. “This is a big step toward a real treatment – and making a real difference.”
Receive an email update when we add a new GLIOBLASTOMA article.
The Latest on: Glioblastoma
via Google News
The Latest on: Glioblastoma
- Duaine N. Kirschbaumon November 30, 2019 at 10:59 am
BARNEVELD - Duaine N. Kirschbaum, age 73, of Barneveld, passed away at home on Thursday, Nov. 28, 2019, after a brief struggle with glioblastoma. He was born on Sept. 15, 1946, in Platteville, the son ...
- Exploring drug repurposing to treat glioblastomaon November 27, 2019 at 6:33 am
MALT1 blockers have long been in clinical use for the treatment of blood cancers. A study suggests that these drugs could potentially also be developed as a treatment option for glioblastoma, the most ...
- Australia’s Kazia Therapeutics reports positive interim results in phase II glioblastoma trialon November 26, 2019 at 3:18 pm
PERTH, Australia – Sydney-based Kazia Therapeutics Ltd.’s shares soared nearly 82% this week on positive interim results for lead molecule GDC-0084 in a phase II glioblastoma trial. Data from the ...
- Diffusion Pharmaceuticals' TSC: Thoughts On The Potential For Its Glioblastoma Indicationon November 26, 2019 at 3:22 am
Diffusion Pharmaceuticals is a tiny micro-cap with market cap between $4.6m and $11.1m (based on a price of $0.285), developing an add-on treatment for brain cancer (glioblastoma) and stroke. The ...
- EpicentRx Announces Positive Results From Phase 1 Trial of RRx-001 as First-line Treatment in Newly Diagnosed Glioblastomaon November 25, 2019 at 4:06 pm
Glioblastoma multiforme (GBM) represents 15-20% of all primary intracranial neoplasm, with death typically occurring within the first 15 months after diagnosis. The median age of diagnosis is 64 years ...
- Local man passes away after fight against glioblastomaon November 25, 2019 at 7:33 am
ST. LUCIE COUNTY, Fla. — His story helped bring needed attention to a deadly disease and bring hope to a community of people battling glioblastoma. This week, 35-year-old Mark Cunningham was laid to ...
- Positive Interim Efficacy Data from GDC-0084 Phase II Study in Glioblastoma Released at SNO Conferenceon November 24, 2019 at 3:18 pm
SYDNEY, Nov. 25, 2019 /PRNewswire/ -- Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to share with investors interim data from ...
- Man loses fight against glioblastomaon November 22, 2019 at 8:30 pm
His story helped bring needed attention to a deadly disease and bring hope to a community of people battling glioblastoma. This week, 35-year-old Mark Cunningham was laid to rest after passing away ...
- Musashi1 enhances chemotherapy resistance of pediatric glioblastoma cells in vitroon November 22, 2019 at 1:45 am
Glioblastoma (GBM) is the most aggressive form of glioma in adults and children and is associated with very poor prognosis. Pediatric tumors are biologically distinct from adult GBM and differ in ...
via Bing News